| Chapter title |
NTBC and Correction of Renal Dysfunction
|
|---|---|
| Chapter number | 8 |
| Book title |
Hereditary Tyrosinemia
|
| Published in |
Advances in experimental medicine and biology, January 2017
|
| DOI | 10.1007/978-3-319-55780-9_8 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-955779-3, 978-3-31-955780-9
|
| Authors |
Arianna Maiorana, Carlo Dionisi-Vici |
| Abstract |
Hereditary tyrosinemia type 1 (HT1) is characterized by severe progressive liver disease and renal tubular dysfunction. Kidney involvement is characterized by hypophosphatemic rickets and Fanconi syndrome. Different animal models were useful to investigate the pathophysiology of the disease and the effects of NTBC therapy on liver and kidney function. NTBC has revolutionized the prognosis of HT1 and its acute and chronic effects on renal tubular function have been proved, with normalization of tubular function within a few weeks, particularly hypophosphatemia and proteinuria. NTBC therapy is highly effective in improving renal function both at short and long-term. However, its efficacy critically depends on the age at start of treatment with normal outcome in patients diagnosed at birth by newborn screening. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 18% |
| Student > Ph. D. Student | 3 | 18% |
| Student > Master | 2 | 12% |
| Researcher | 2 | 12% |
| Professor | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 4 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 18% |
| Nursing and Health Professions | 2 | 12% |
| Economics, Econometrics and Finance | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 4 | 24% |